CARLSBAD, Calif., April 9, 2024 /PRNewswire/ -- Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications announces the launch of its new multiplex spatial biology assay services for rapid, whole-slide imaging and analysis of tissue sections at subcellular resolution.

加利福尼亚州卡尔斯巴德，2024年4月9日/PRNewswire/--Navigate BioPharma Services，Inc.是一家专业实验室，为临床开发和诊断应用提供高质量，创新的精密医学解决方案和生物分析，宣布推出其新的多重空间生物学分析服务，用于亚细胞分辨率下组织切片的快速，全幻灯片成像和分析。

These assays utilize the Orion™ platform from RareCyte, Inc. and feature ready-to-run assay panels, as well as customization to serve multiple drug targets and therapeutic areas..

这些分析利用RareCyte，Inc.的Orion™平台，并具有随时可用的分析面板，以及定制以服务于多种药物靶标和治疗领域。。

This collaboration aims to leverage the complementary expertise of both companies to provide end-to-end spatial biology services for pharmaceutical and clinical institutions worldwide. The RareCyte Orion™ platform has been used to understand a range of diseases, to elucidate highly prognostic biomarkers for diagnosis and to study the mechanism of action of neoadjuvant immune therapies.

此次合作旨在利用两家公司的互补专业知识，为全球制药和临床机构提供端到端的空间生物学服务。RareCyte Orion™平台已被用于了解一系列疾病，阐明用于诊断的高度预后生物标志物，并研究新辅助免疫疗法的作用机制。

Navigate BioPharma provides years of experience in developing high-plex imaging assays and creating highly customized biomarker solutions for immuno-oncology and oncology clinical trials. The Orion platform enables Navigate BioPharma to expand the degree of customization and depth of biomarker data that can be assessed to inform clinical decisions..

Navigate BioPharma在开发高倍数成像分析和为免疫肿瘤学和肿瘤学临床试验创建高度定制的生物标志物解决方案方面提供了多年的经验。Orion平台使Navigate BioPharma能够扩大可评估的生物标志物数据的定制程度和深度，从而为临床决策提供信息。。

Over the past years, Navigate BioPharma has developed and validated over 125 unique multiplex immunofluorescence (mIF) assays. The new multiplex spatial biology service offerings enable an increased combination of biomarkers to be analyzed concurrently, providing a more holistic evaluation of the tumor microenvironment.

在过去的几年中，Navigate BioPharma已经开发并验证了超过125种独特的多重免疫荧光（mIF）检测方法。新的多重空间生物学服务产品能够同时分析更多的生物标志物组合，从而对肿瘤微环境进行更全面的评估。

'Using a one-shot stain and scan quantitation of up to twenty biomarkers simultaneously, as well as same-slide H&E imaging to support AI-driven drug discovery and development, the Orion™ platform further enhances our (Navigate's) robust mIF capabilities,' said Jennifer Bourdeaux, Associate Director of Digital Pathology at Navigate BioPharma Services, Inc.

Navigate BioPharma Services，Inc.数字病理学副主任詹妮弗·波尔多（JenniferBourdeaux）说：“Orion™平台使用一次性染色和同时扫描定量多达20种生物标志物，以及相同的幻灯片H＆E成像来支持人工智能驱动的药物发现和开发，进一步增强了我们（Navigate）强大的mIF功能。”。

With high sensitivity, a broad dynamic range and single-cell resolution to provide whole-slide data, Orion™ assays deliver insights for established drug targets and therapeutic candidate clinical trials alike..

Orion™分析具有高灵敏度、宽动态范围和单细胞分辨率，可提供完整的载玻片数据，可为已建立的药物靶标和治疗候选临床试验提供见解。。

Further enhancing the partnership, Navigate BioPharma provides their expertise in creating custom assays for specific research problems and for use in sponsor-led clinical trials as trusted member of RareCyte's Qualified Service Providers (QSPs). 'Navigate BioPharma has the full support of RareCyte's scientists and engineers to ensure the highest quality of assay development, imaging, and analysis using the Orion platform,' said Selena Larkin, Chief Commercial Officer of RareCyte, Inc..

Navigate BioPharma作为RareCyte合格服务提供商（QSP）的可信成员，进一步加强了合作关系，为特定研究问题创建定制检测方法并用于赞助商主导的临床试验提供了专业知识RareCyte，Inc.首席商务官赛琳娜·拉金（SelenaLarkin）说，Navigate BioPharma得到了RareCyte科学家和工程师的全力支持，以确保使用猎户座平台进行最高质量的分析开发、成像和分析。。

About RareCyte, Inc.

关于RareCyte，Inc。

RareCyte is an innovative precision biology company that develops technologies and end-to-end integrated platforms enabling advances in oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. As a leading Life Sciences company, our team of scientists and engineers are continuously dedicated to design products and provide services which advance precision medicine and biomedical research, ensure successful clinical development programs, and contribute to companion diagnostic development.

RareCyte是一家创新的精密生物学公司，开发技术和端到端集成平台，实现肿瘤学，免疫肿瘤学，母胎健康以及细胞和基因治疗的进步。作为一家领先的生命科学公司，我们的科学家和工程师团队不断致力于设计产品和提供服务，以推进精准医学和生物医学研究，确保成功的临床开发计划，并为伴随的诊断开发做出贡献。

About Navigate BioPharma

关于导航生物制药

Navigate BioPharma Services, Inc., an independently operating subsidiary within the Novartis group of companies, is a leading provider of innovative biomarker and specialty bioanalytic solutions for clinical development and companion diagnostic applications. Over the past decade, Navigate BioPharma has built and developed its exclusive library of assays, methodologies, and biomarker solutions.  The company has a proven track record of success in developing and validating assays for a wide range of therapeutic and diagnostic applications.

Navigate BioPharma Services，Inc.是诺华集团旗下的一家独立运营子公司，是临床开发和伴随诊断应用的创新生物标志物和专业生物分析解决方案的领先供应商。在过去的十年中，Navigate BioPharma建立并开发了其独家的分析，方法和生物标志物解决方案库。该公司在为广泛的治疗和诊断应用开发和验证检测方法方面取得了成功。

Their extensive expertise offers high-quality, accurate, and reliable solutions for its customers and partners to make informed decisions about drug development and patient care.

他们广泛的专业知识为其客户和合作伙伴提供了高质量，准确和可靠的解决方案，以做出有关药物开发和患者护理的明智决策。